Biomaterials for direct cardiac repair-A rapid scoping review
2012-2022

J 2024

Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI et. al.

Basic information

Original name

Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022

Authors

SEDLÁKOVÁ, Veronika (203 Czech Republic, belonging to the institution), Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN and Emilio I ALARCON

Edition

ACTA BIOMATERIALIA, London, ELSEVIER SCI LTD, 2024, 1742-7061

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 9.700 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.actbio.2024.04.008

UT WoS

001240708500001

Keywords in English

Heart disease; Clinical trial; Scoping review; Multi-database searching

Abstract

V originále

A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically.

Citovat

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN and Emilio I ALARCON. Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022. ACTA BIOMATERIALIA. London: ELSEVIER SCI LTD, 2024, vol. 180, May 2024, p. 61-81. ISSN 1742-7061. Available from: https://dx.doi.org/10.1016/j.actbio.2024.04.008.

@article{2403757,
   author = {Sedláková, Veronika and Mourcos, Sophia and Pupkaitė, Justina and Lunn, Yvonne and Visintini, Sarah and GuzmanandSoto, Irene and Ruel, Marc and Suuronen, Erik and Alarcon, Emilio I},
   article_location = {London},
   article_number = {May 2024},
   doi = {http://dx.doi.org/10.1016/j.actbio.2024.04.008},
   keywords = {Heart disease; Clinical trial; Scoping review; Multi-database searching},
   language = {eng},
   issn = {1742-7061},
   journal = {ACTA BIOMATERIALIA},
   title = {Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022},
   url = {https://www.sciencedirect.com/science/article/pii/S1742706124001818},
   volume = {180},
   year = {2024}
}

TY  - JOUR
ID  - 2403757
AU  - Sedláková, Veronika - Mourcos, Sophia - Pupkaitė, Justina - Lunn, Yvonne - Visintini, Sarah - Guzman-Soto, Irene - Ruel, Marc - Suuronen, Erik - Alarcon, Emilio I
PY  - 2024
TI  - Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022
JF  - ACTA BIOMATERIALIA
VL  - 180
IS  - May 2024
SP  - 61-81
EP  - 61-81
PB  - ELSEVIER SCI LTD
SN  - 17427061
KW  - Heart disease
KW  - Clinical trial
KW  - Scoping review
KW  - Multi-database searching
UR  - https://www.sciencedirect.com/science/article/pii/S1742706124001818
N2  - A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically.
ER  -

SEDLÁKOVÁ, Veronika, Sophia MOURCOS, Justina PUPKAITĖ, Yvonne LUNN, Sarah VISINTINI, Irene GUZMAN-SOTO, Marc RUEL, Erik SUURONEN and Emilio I ALARCON. Biomaterials for direct cardiac repair-A rapid scoping review 2012-2022. \textit{ACTA BIOMATERIALIA}. London: ELSEVIER SCI LTD, 2024, vol.~180, May 2024, p.~61-81. ISSN~1742-7061. Available from: https://dx.doi.org/10.1016/j.actbio.2024.04.008.

Detailed Information on Publication Record